ImmuCell Balance Sheet Health
Financial Health criteria checks 5/6
ImmuCell has a total shareholder equity of $26.4M and total debt of $10.9M, which brings its debt-to-equity ratio to 41.3%. Its total assets and total liabilities are $44.4M and $18.0M respectively.
Key information
41.3%
Debt to equity ratio
US$10.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.81m |
| Equity | US$26.41m |
| Total liabilities | US$18.04m |
| Total assets | US$44.45m |
Recent financial health updates
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Nov 30
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Recent updates
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 04ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Nov 30Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price
Aug 07ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price
May 27ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22ImmuCell reports FY20 preliminary sales
Jan 07ImmuCell restructures its bank debt
Dec 15ImmuCell EPS beats by $0.04, beats on revenue
Nov 12Financial Position Analysis
Short Term Liabilities: ICCC's short term assets ($13.9M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: ICCC's short term assets ($13.9M) exceed its long term liabilities ($13.6M).
Debt to Equity History and Analysis
Debt Level: ICCC's net debt to equity ratio (26.9%) is considered satisfactory.
Reducing Debt: ICCC's debt to equity ratio has increased from 29.9% to 41.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICCC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ICCC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 14.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 13:06 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |